Table 3.

Summary of treatment After ASSP therapy.

PCR	Drug	Study population (n)	Day-3 positive parasite	ETF (n)	LTF (n)	ACPR (n)	Recrudescence (n)	Re-infection (n)
PCR uncorrected	ASSP	180	9 (5%)	7a (3.9%)	12 (6.7%)	159 (88.3%)	–	–
PCR corrected	ASSP	180	9 (5%)	7a (3.9%)	10b (5.6%)	161 (89.4%)	10 (5.6%)	2 (1.1%)

ACPR, ETF and LTF stand for adequate clinical parasitological response, early treatment failure and late treatment failure, respectively, whereas ASSP stand for artemisinin-sulfadoxine-pyrimethamine.

^aOne patient did not attain the adequate plasma DHA concentration and in another patient, we failed to adapt the in vitro culture for RSA assay.

^bInitially reappearance of infection was observed in 12 patients (6.7%), but analyses of msp1, msp2, and glurp gene confirmed that among those 12 patients, 10 (5.5%) were true recrudescence (LTF) case.